Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 6/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3851051 | 0.89 | NPC1 (0.31) | NPC1RAB9AS1PR3ALDH1A1TP53 | |
| SCHEMBL11849077 | 0.86 | NPC1 (0.42) | NPC1RAB9AS1PR3RETSMYD3 | |
| SCHEMBL4401708 | 0.83 | KDM4E (0.42) | NPC1RAB9AS1PR3ALDH1A1TP53 | |
| SCHEMBL4917420 | 0.78 | HCRTR1 (0.35) | NPC1RAB9ARETDRD2DRD4 | |
| SCHEMBL4919068 | 0.76 | NISCH (0.35) | NPC1RAB9ARETALDH1A1 | |
| SCHEMBL4911781 | 0.75 | CHRNB2 (0.38) | NPC1RAB9AS1PR3RETDRD2 | |
| SCHEMBL4911776 | 0.75 | CHRNB2 (0.38) | NPC1RAB9AS1PR3RETDRD2 | |
| SCHEMBL4912257 | 0.75 | RET (0.36) | NPC1RAB9ARET | |
| SCHEMBL4918790 | 0.75 | CYP1A1 (0.33) | NPC1RAB9ARET | |
| SCHEMBL4917615 | 0.75 | RET (0.34) | NPC1RAB9ARET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161278-A1 | 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| EP-1863797-A1 | 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100461-A1 | 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161278-A1 | 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity | IGF1R, IGFBP1, IGFBP2 | NPC1 3497/4885RAB9A 3605/4885S1PR3 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.